2020
Press releases and abstracts for each press conference presentation are available at these links:
Updated monarchE Trial Data Shows Abemaciclib Continues to Benefit Patients With High-risk, HR-positive, HER2-negative, Early-stage Breast Cancer
Postmenopausal Women With Early-stage Breast Cancer and Low Recurrence Score Could Skip Adjuvant Chemotherapy
Under-recognition of Symptoms May Be Common in Patients With Breast Cancer Receiving Radiotherapy
Women Who Undergo Mastectomy and Reconstructive Surgery May Be at Risk of Becoming Persistent Drug Users
Circulating Tumor Cell Dynamics May Predict Treatment Response and Prognosis in Patients with Metastatic Breast Cancer
Omitting Radiation Therapy After Breast-Conserving Surgery May Not Impact 10-year Survival Rates for Older Patients With HR-positive Breast Cancer
Breast Cancer Survivors Are Less Likely to Get Pregnant, but Often Have Healthy Babies and Good Long-term Health
Please note that in some cases, data may have been updated since the abstracts were submitted. The press releases contain the most up-to-date information.
2019
Breast cancer researcher to receive memorial lecture award
Researchers to be honored at San Antonio Breast Cancer Symposium
The 2019 San Antonio Breast Cancer Symposium: What to Expect
Breast Cancer Meeting ‘Is Going to Be Spectacular’
Emerging Alternatives in the Third-Line Setting for Metastatic HER2-Positive Breast Cancer
FDA Pipeline: Treatments for HER2-Positive Breast Cancer, AML; Breakthrough Device for Prostate Cancer; Statement on Safety Information for Breast Implants
San Antonio medical school gets millions to research breast cancer
Adjuvant T-DM1 Approaches EU Approval for HER2+ Early Breast Cancer
MacroGenics’ Metastatic Breast Cancer Drug Shows Survival Benefits in Phase III Trial
Tucatinib Shows Positive Results in Pivotal Trial in Locally Advanced HER2+ Breast Cancer
Novel Anti-HER2 Agents Look to Change Practice at SABCS
Five Key Studies at the San Antonio Breast Cancer Symposium 2019 Conference
Retrospective review: Proton therapy well tolerated in patients undergoing breast conserving surgery
Press Program Coverage
December 11, 2019
New HER2 Antibody-drug Conjugate Yielded Promising Clinical Responses in Breast Cancer Patients Pretreated with T-DM1
- The New York Times
- Los Angeles Times
- US News & World Report
- ABC News
Advisory: Adding Tucatinib to Trastuzumab and Chemotherapy Improves Survival for Patients with Metastatic HER2-Positive Breast Cancer
Addition of S-1 to Post-operative Endocrine Therapy Improves Outcomes for Patients with Hormone Receptor-positive, HER2-negative Breast Cancer
Updated APHINITY Trial Data Show Addition of Pertuzumab to Trastuzumab Plus Chemotherapy Continues to Yield Clinical Benefit in Patients With Operable HER2-positive Early Breast Cancer
Combining Endocrine Therapy with a CDK4/6 Inhibitor Results In Similar Response Rates to Chemotherapy for High-Risk Luminal B Breast Cancer
December 12, 2019
Neoadjuvant Treatment with Pembrolizumab Improves Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer with Lymph Node Involvement
Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer
Breast Cancer Preventive Effects of Anastrozole Persist Long After Stopping Treatment
Partial Breast Irradiation May be as Effective as Whole Breast Irradiation in Preventing Recurrence in Patients with Early Breast Cancer
MINDACT Trial Data Reveal Certain Women With Luminal Breast Cancer May Be Undertreated With Tamoxifen Alone (The decreased media coverage is due to Dr. Cardoso as a no-show for all on-site interviews.)
December 13, 2019
Long-term Follow-up Shows Estrogen Alone and Estrogen Plus Progestin Have Opposite Effects on Breast Cancer Incidence in Postmenopausal Women
Residual Cancer Burden Can Predict Outcomes for Patients With Any Breast Cancer Type
Circulating Tumor DNA May Help Predict Recurrence in Patients with Early Triple-Negative Breast Cancer
Oral Paclitaxel Yielded Better Outcomes Than Intravenous Paclitaxel for Metastatic Breast Cancer Patients in Phase III Trial
Additional SABCS Coverage
Everyday Health
Daily Mail
OncLive
Pharmacy Times
Cancer Therapy Advisor
The Medical News
Medscape
MedPage Today
The Cancer Letter
San Antonio Express-News
The ASCO Post
- SABCS 2019: [Fam-] Trastuzumab Deruxtecan in Patients With Pretreated HER2-Positive Metastatic Breast Cancer
- SABCS 2019: Adding Tucatinib to Capecitabine/Trastuzumab Improved Survival for Patients With Advanced HER2-Positive Breast Cancer
- Subcutaneous Fixed-Dose Pertuzumab/Trastuzumab Proves Noninferiority Versus IV Drugs
- Terry P. Mamounas, MD, MPH, on Extending Letrozole Treatment in Hormone Receptor–Positive Breast Cancer
- Hongchao Pan, PhD, on an Update on 5 Years of Endocrine Therapy for Early Breast Cancer
- Nadine M. Tung, MD, on HER2-Negative Breast Cancer: INFORM Trial of Cisplatin vs Doxorubicin/Cyclophosphamide
- Ivana Sestak, PhD, on Clinical Treatment Score From TAILORx: Predicting Distant Breast Cancer Recurrence
- Marie-Jeanne T.F.D. Vrancken Peeters, MD, PhD, on Omitting Breast Surgery: Results of the MICRA Trial
- Ariella B. Hanker, PhD, on Therapeutic Implications of HER2 and HER3 Mutations in Breast Cancer
- Joerg Heil, MD, PhD, on Image-Guided Vacuum-Assisted Breast Biopsy
- Hope S. Rugo, MD, on HER2-Positive Metastatic Breast Cancer: SOPHIA Trial of Chemotherapy Plus Margetuximab or Trastuzumab
- Javier Cortes, MD, PhD, on Triple-Negative Breast Cancer: Results From the KEYNOTE-119 Trial of Pembrolizumab vs Chemotherapy
- Joseph Sparano, MD: The William L. McGuire Memorial Lecture
- Belinda Kingston, MB ChB, on the Genomic Landscape of Breast Cancer Based on ctDNA Analysis
- Tari A. King, MD, on Molecular Differences Between Primary and Metastatic Breast Tumors
- Rashmi K. Murthy, MD, on HER2-Positive Metastatic Breast Cancer: HER2CLIMB Trial of Tucatinib, Capecitabine, and Trastuzumab
- Nicholas C. Turner, MD, PhD, on ctDNA Testing to Direct Targeted Therapies in Advanced Breast Cancer
- Priyanka Sharma, MD, on Postoperative Treatment of Primary Breast Cancer: POTENT Trial
- Ralph R. Weichselbaum, MD, on Oligometastatic Cancer: The Role of Radioimmunotherapy
- Miguel Martín, MD, PhD, on Metastatic Breast Cancer: PEARL Trial on Palbociclib Plus Endocrine Therapy vs Capecitabine
- Sara M. Tolaney, MD, MPH, on HER2-Positive Breast Cancer: ATEMPT Trial on T-DM1 vs Paclitaxel Plus Trastuzumab
MDEdge
Onco’Zine
Cancer Network
ecancer
The Center for Biosimilars
Breastcancer.org
Healio